MAP2K1 K57N

CI-VAR-00002145Explore in graph →NP_002746.1:p.Lys57AsnNM_002755.3:c.171G>TClinVar 223140 CIViC 1272 rs869025608

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
MAP2K1 K57N	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID2935 In a study of 6,024 lung adenocarcinomas, 36 conferred MEK1 mutations whereby 64% (n=23) were K57N and 19% (n=7) were Q56P. Median overall survival of MEK1-mutated tumors was not significantly differe… (full text at CIViC) PMID 25351745 · Arcila et al., 2015 · Open in CIViC	civic
MAP2K1 K57N	Selumetinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID2936 Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known… (full text at CIViC) PMID 18632602 · Marks et al., 2008 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
MAP2K1 K57N	Selumetinib	Predictive	C	Supports Resistance	3	submitted	EID7709 In a phase 2 clinical trial, patients with BRAF V600-mutated melanoma were treated with selumetinib. One patient whose tumor did not response had a MAP2K1 K57N mutation. PMID 23444215 · Catalanotti et al., 2013 · Open in CIViC	civic